Combinatorial therapy for cancer: A therapeutic mix encompassing Metformin and Navitoclax/ABT-263 (MAN) increases the expression of mitochondrial protein LACTB, decreases levels of mitochondrial phosphatidylserine decarboxylase, alters mitochondrial lipid metabolism, and promotes differentiation of breast cancer cells via up-regulation of its target gene, 12/February/2018, 10.31 pm

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA HEIH  increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 12/Februay/2019, 10.21 pm
February 12, 2019
Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA PCGEM1 (Prostate-specific transcript 1)  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and ageing, via down-regulation of its target gene, 12/February/2019, 11.14 pm
February 12, 2019
Show all

Introduction: What they say:

A study from the Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts, USA, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA; and MIT Ludwig Center for Molecular Oncology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA shows that “LACTB is a tumor suppressor that modulates lipid metabolism and cell state” This study was published, in the 22 March 2017 issue of the journalNature” [One of the best journals in General Science with an I.F of 43 plus], by Prof. Robert A Weinberg, Zuzana Keckesova, and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Combinatorial therapy for cancer: A therapeutic mix encompassing Metformin and Navitoclas/ABT-263 (MAN) increases the expression of mitochondrial protein LACTB, decreases levels of mitochondrial phosphatidylserine decarboxylase, alters mitochondrial lipid metabolism, and promotes differentiation of breast cancer cells via up-regulation of its target gene

Price 300

[easy_payment currency=”USD”]


From Significance of the study to Public health relevance:

Given that: (i) each year nearly 14 million people are diagnosed with cancer globally; (ii) cancer deaths globally are expected to be doubled in a little more than decades time; (iii) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide; (iv) Breast cancer not only the most common women cancer, but also the most common invasive cancer in women; (v) Breast cancer not only metastasizes frequently, but also relapses; (vi) in 2008, breast cancer has caused more than 400000 deaths; and it is the second leading cause of cancer death in women; (vii) in 2008, breast cancer has caused economic loss of 88 billion US dollars worldwide; (viii) cancer causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) a way to activate cancer patients immune system against tumors (Cancer immunotherapy); (ii) a cheaper alternative to the existing expensive anticancer drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to effectively treat and prevent metastatic progression and relapse of cancers.


What we infer from what they say:

Prof. Bob Weinberg’s research team has recently shown that mitochondrial protein LACTB: (1) inhibits proliferation of breast cancer cells; (2) alters mitochondrial lipid metabolism; (3) decreases the levels of mitochondrial phosphatidylserine decarboxylase (required for the synthesis of mitochondrial phosphatidylethanolamine); (4) promotes differentiation of breast cancer cells, suggesting that induction of LACTB in breast cancer cells may inhibit its proliferation.


From research findings to therapeutic opportunity :

This study suggests a combinatorial therapy for human cancers.  A therapeutic mix encompassing Metformin and Navitoclax/ABT-263 (MAN), by increasing the expression of its target genes, it may increase the expression of LACTB (fig. 1). Thereby, it may: (i) stall proliferation of breast cancer cells; (ii) alter mitochondrial lipid metabolism; (iii) decrease mitochondrial phosphatidylserine decarboxylase levels; (iv) decrease mitochondrial phosphatidylethanolamine levels; and (v) promote differentiation of breast cancer cells (fig.1).

Figure 1. Mechanistic insights into how a therapeutic mix encompassing Metformin and Navitoclax/ABT-263 (MAN) increases the expression of tumor suppressor LACTB and promote differentiation of tumor cells

Figure 2. A therapeutic mix encompassing Metformin and Navitoclas/ABT-263 (MAN) functions as an anti-cancer agent.

Thus, pharmacological formulations encompassing “Metformin and Navitoclax/ABT-263 (MAN), either alone or in combination with other known anticancer drugs or probiotics,” may be used to inhibit tumor proliferation and promote tumor differentiation.


Details of the Research findings:

Idea Proposed/Formulated (with experimental evidence) by Dr L Boominathan Ph.D.

Amount: $300#

Undisclosed mechanistic information: How does a therapeutic mix encompassing Metformin and Navitoclax/ABT-263 (MAN) increase the expression of LACTB ?

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

#Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Combinatorial therapy for cancer: A therapeutic mix encompassing Metformin and Navitoclax/ABT-263 (MAN) increases the expression of mitochondrial protein LACTB, decreases levels of mitochondrial phosphatidylserine decarboxylase, alters mitochondrial lipid metabolism, and promotes differentiation of breast cancer cells via up-regulation of its target gene, 12/February/2018, 10.31 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, Kindly drop us a line at admin@genomediscovery.org

Comments are closed.